An interventional study of Sarcopenia screening assessment in Juvenile Idiopathic Arthritis, sponsored by CHU de Reims. Not yet recruiting at 1 site in France. Open to participants aged 15 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by CHU de Reims · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Arthritis, Juvenile with a site in France — 18 open to participants now, 21 under way, 9 of them phase 3. Arthritis, Juvenile · France.
Among the 71 studies in Arthritis, Juvenile with a site in France, this one is the 8th largest by planned enrollment of the 50 interventional ones that give a count, is one of 4 that started in 2026, is one of 13 with no phase, reaches primary completion later than 9 of the 20 other live ones, and was the 70th registered.
367 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
Browse Arthritis, Juvenile studies →18 of the 71 studies in Arthritis, Juvenile with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 2–16
Alfasigma S.p.A. · Sites in France, Belgium, Czechia and 6 more countries
Ages 8–18
Alfasigma S.p.A. · Sites in France, Germany, United Kingdom
Ages 8–18
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Novartis Pharmaceuticals · Sites in France, United States, Canada and 5 more countries
Ages 1+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.
This study: 15 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 28
First in 2000; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 61 across the 50 interventional studies, 274 across the 21 observational. Of the 42 that completed or were terminated, 16 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 71 have an industry lead sponsor. The 10 most frequent:
CHU de Reims is the lead sponsor of 276 studies on the registry; 50 are open to participants now.
CHU de Reims has 1 study filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
5 of the studies in Arthritis, Juvenile with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07554495Phase 3Alfasigma S.p.A.Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents | 2027-06 |
| NCT07203001Novartis PharmaceuticalsA Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease | 2027-04-22 |
| NCT05927454Institut National de la Santé Et de la Recherche Médicale, FranceAcostill ( RaDiCo Cohort) (RaDiCo Acostill) | 2027-07 |
| NCT07077304Assistance Publique - Hôpitaux de ParisEACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases | 2027-08-31 |
| NCT07634354CHU de ReimsSarcopenia and Juvenile Idiopathic Arthritis | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 71 studies in Arthritis, Juvenile with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Juvenile idiopathic arthritis (JIA) is a rare chronic inflammatory rheumatic disease that begins during childhood and may persist into adulthood in many patients. In addition to joint pain, swelling, and long-term articular damage, chronic inflammatory diseases may also be associated with early sarcopenia, defined as a loss of muscle strength and muscle mass. While this association has been described in adult inflammatory rheumatic diseases, it has not been well studied in patients with JIA.
The aim of this study is to screen for sarcopenia in adolescents and adults with JIA in France. Sarcopenia will be assessed using validated questionnaires, hand grip strength measured with a Jamar dynamometer, and body composition measured by dual-energy X-ray absorptiometry (DEXA). Completion of validated questionnaires will assess nutritional status, fatigue, physical activity, and functional impact. Socio-demographic and clinical data will also be collected from medical records.
This multicenter cross-sectional study will be conducted between June 2026 and October 2027 in 11 French hospitals. Eligible participants are patients aged 15 to 40 years with JIA diagnosed according to ILAR criteria and followed in a French hospital.
This study will provide the first estimate of sarcopenia prevalence among patients with JIA in France. It will also help identify factors associated with sarcopenia and its impact on daily functioning and quality of life. In the longer term, the findings may help clinicians better identify patients at risk and support earlier management focused on disease control, physical activity, and nutritional care.
This is a national multicenter cross-sectional study conducted in 11 French hospitals between June 2026 and October 2027. The study aims to assess sarcopenia in adolescents and adults with juvenile idiopathic arthritis (JIA) during a routine rheumatology follow-up visit.
After receiving study information and providing informed consent (with parental/legal guardian consent for minors, according to applicable regulations), participants will undergo a standardized single study assessment during routine care. This assessment will include measurement of hand grip strength using a Jamar dynamometer, whole-body dual-energy X-ray absorptiometry (DEXA) for body composition and appendicular lean mass evaluation, and completion of validated questionnaires addressing nutritional status, fatigue, physical activity, and functional impact. Additional socio-demographic and clinical data related to JIA history, disease characteristics, and treatments will be collected from medical records.
The study is designed to estimate the prevalence of sarcopenia in patients with JIA in France and to explore factors associated with sarcopenia and its functional impact. If sarcopenia is identified, additional management may be proposed by the treating physician as part of usual care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In the case of a minor patient, the consent of the patient and their legal guardians is required.
exclusion criteria :
Single group of adolescents and adults with juvenile idiopathic arthritis undergoing a standardized sarcopenia screening assessment at inclusion.
Other: Sarcopenia screening assessment
Participants will undergo a standardized single-visit assessment including hand grip strength measurement, whole-body DEXA scan for body composition, validated questionnaires, and collection of socio-demographic and clinical data from medical records.
Sarcopenia
A cross-sectional assessment of sarcopenia for each included patient will be performed at a participating hospital center: Performance of a hand grip test using a hand dynamometer (3 consecutive measurements on the dominant hand) and a whole-body DEXA scan with measurement of the appendiceal mass index Confirmation by the best grip test value \< -2 SD according to the patient's age and sex on the reference curves associated with a pathological whole-body DEXA (appendiceal mass index ≤ 7 kg/m2 for men, ≤ 5.5 kg/m2 for women)
Time frame: Day 1
Fatigue assessed by FACIT-F
Fatigue assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire
Time frame: Day 1
Physical activity assessed by IPAQ
Physical activity assessed using the International Physical Activity Questionnaire (IPAQ)
Time frame: Day 1
Functional disability assessed by HAQ-DI
Functional disability assessed using the Health Assessment Questionnaire Disability Index (HAQ-DI).
Time frame: Day 1
Health-related quality of life assessed by SF-12
Health-related quality of life assessed using the 12-Item Short Form Health Survey (SF-12).
Time frame: Day 1
Start is estimated for Jun 2026; primary completion for Oct 2027, 16 months later.
Of 53 non-industry interventional studies with no phase under Arthritis, Juvenile, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 35. This study's planned 16 months is above that.
Counting every sponsor, half of 56 studies reached it within 14 months; a quarter within 8 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.